SAN DIEGO, June 30, 2020 /PRNewswire/ -- Ajinomoto
Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
biopharmaceutical contract development and manufacturing services,
is pleased to announce the launch of AJILITY™, a flexible and agile
drug product manufacturing platform, designed to advance vaccines
and therapies to market by minimizing time to production.
Aji Bio-Pharma's AJILITY platform is designed for novel
therapeutics/vaccines and existing drug products with a new
indication that can be used in COVID-19 trials, FDA Emergency Use
Authorizations (EUA), or other programs, providing enhanced
flexibility by leveraging our existing, streamlined project
configurations. With Aji Bio-Pharma's AJILITY, clients will
have access to our experience and expertise to guide them through
decisions from components and excipients to method qualifications.
The goal of the AJILITY platform is to minimize variables during
tech transfer, manufacturing and shipping processes and rely on our
regulatory expertise to navigate traditional production hurdles to
quickly get therapies to clinics.
"The AJILITY platform offers flexibility and time savings, which
is an enormous boost those clients with drug products that need to
get to clinical trials quickly," said Dustin Campbell, Associate Director of
Commercial Operations at Ajinomoto Bio-Pharma Services. "As a
leading CDMO for drug product manufacturing, we understand that
some program details affect the manufacturing timeline more than
others. The AJILITY platform utilizes Aji Bio-Pharma's extensive
experience in manufacturing and regulatory insight to fast track
our clients' programs to market."
"We are excited to introduce the AJILITY platform to our client
base interested in our progressive partnering approach to advance
their therapeutic to patients," said Kristin DeFife, Ph.D., Sr. VP of Operations
& Site Head at Ajinomoto Bio-Pharma Services. "The AJILITY
platform was developed by a cross-functional departmental team to
provide our clients access to preferred drug product manufacturing
processes, coupled with our expertise in regulatory submissions,
process development, and shipping configurations at our
San Diego, California
facility."
To learn more about the AJILITY program, visit:
www.AjiBio-Pharma.com/AJILITY.
About Ajinomoto Bio-Pharma Services
Ajinomoto
Bio-Pharma Services is a fully integrated contract development and
manufacturing organization with sites in Belgium, United
States, Japan, and
India, providing comprehensive
development, cGMP manufacturing, and aseptic fill finish services
for small and large molecule APIs and intermediates. Ajinomoto
Bio-Pharma Services offers a broad range of innovative platforms
and capabilities for pre-clinical and pilot programs to commercial
quantities, including Corynex® protein expression
technology, oligonucleotide synthesis, antibody drug conjugations
(ADC), high potency APIs (HPAPI), biocatalysis, continuous flow
manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated
to providing a high level of quality and service to meet our
client's needs. Learn more: www.AjiBio-Pharma.com
Logo -
https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg